

5 November 2020

Mr Ron Kaushik
Senior Manager – Market Surveillance
NSX Limited
1 Bligh Street
Sydney, NSW 2000

Re: Response to NSX Periodic Disclosure Query of 29 October 2020

Dear Mr Kaushik

The iQ Group Global Ltd (ACN 149 731 644) (the “Company”) responds to the requests for information included in your periodic disclosure query as follows.

The requests for information relate to Ethical Bioscience Investments Fund Pty Ltd (ACN 612 952 360) (“EBI”), an unlisted entity which is owned 50% by IQG and 50% by iQX Limited (ACN 155 518 380) (“iQX”).

Responses to the requests for information are set out below:

- 1/ The fixed term debt instruments offered by EBI referenced in note 25(iii) to the Company’s 2020 annual report are the EBI Fixed Income Notes. Current EBI fixed income products include those identified on EBI’s website. Available products change according to underlying investment opportunities and conditions in the financial markets.
- 2/ Investments by EBI are made in accordance with the investment strategy as determined by the investment committee of EBI from time to time. EBI is a corporate authorised representative (Australian Financial Services License Auth. Rep. No. 001246020) of iQX Investment Services Pty Ltd (ACN 163 056 371; Australian Financial Services License No. 451144). EBI has appointed Lanterne Fund Services Pty Ltd (ACN 098 472 587; Australian Financial Services License No. 238198) (“Lanterne”) as its authorised intermediary pursuant to section 911A(2)(b) of the *Corporations Act 2001* (Cth). Under this arrangement, it has been agreed that Lanterne will make offers to sophisticated investors (within the meaning of section 708(8) of the *Corporations Act 2001* (Cth)) to arrange for the issue of the EBI Fixed Income Notes and EBI will issue the EBI Fixed Income Notes in accordance with such offers, if they are accepted. Lanterne is authorised to provide certain financial services, including dealing in a financial product by arranging for another person to issue, apply for or acquire securities. EBI and its related bodies corporate are not deposit-taking

institutions in Australia and are not authorised to conduct retail banking activities under the *Banking Act 1959* (Cth).

- 3/ The joint venture shareholders agreement reflects the initial 50% shareholding in EBI by each of the Company and iQX, and reflects the agreement of each of the Company and iQX that investments by EBI will be made in accordance with the investment strategy as determined by the investment committee of EBI from time to time.
- 4/ Investments by EBI are made in opportunities across the global bioscience sector. These assets are selected based on expected growth potential and planned liquidity events to facilitate the payment of interest on, and repayment of principal in respect of, the EBI Fixed Income Notes.
- 5/ Amounts invested by investors in the EBI Fixed Income Notes are recorded as liabilities in the financial statements of EBI. Disclosures in the Company's audited financial statements are made in accordance with applicable accounting standards.
- 6/ Offers of fixed term debt instruments by EBI are only made to sophisticated investors (within the meaning of section 708(8) of the *Corporations Act 2001* (Cth)) and/or other wholesale investors. These offers do not require disclosure pursuant to Part 6D.2 or Part 7 of the *Corporations Act 2001* (Cth). Information memoranda and other materials in relation to EBI Fixed Income Notes are confidential and for the sole use of prospective investors and their advisers; information memoranda and such other materials are provided on the condition that the recipient is a sophisticated investor and that such materials must not be provided to any other party without the written consent of EBI. EBI takes steps to ensure that information memoranda and other materials in relation to EBI Fixed Income Notes are not made available to retail investors and does not accept applications from retail investors in respect of EBI Fixed Income Notes. Consistent with these precautions, the Company does not wish to provide copies of information memoranda and other materials in relation to the EBI Fixed Income Notes in response to this request.
- 7/ No assets have been acquired or disposed of by the Company in circumstances implicating NSX Listing Rule 6.43.
- 8/ Pursuant to NSX Listing Rule 6.4, an issuer is required to keep the Exchange informed without delay, for dissemination, of any information relating to the group of which it is aware that:
 - (1) is necessary to enable the Exchange and the public to appraise the financial position of the issuer and the group; or

- (2) is necessary to avoid the establishment of a false market in the issuer's securities; or
- (3) a reasonable person would expect to have a material effect on the price or value of the issuer's securities.

The Company does not consider that the incorporation of EBI was required to be disclosed pursuant to NSX Listing Rule 6.4. The Company does not believe that disclosure of the establishment of the EBI business was required in order to enable appraisal of the financial condition of the Company or the group, or to avoid the establishment of a false market. As the EBI Fixed Income Notes are unsecured and are not guaranteed by the Company or any of the Company's subsidiaries, the Company considers that establishment of the EBI business would not be expected to have a material effect on the price or value of the Company's securities. At such time as the EBI business has an established operating history and operations of a significance that would be expected to have a material effect on the price or value of the Company's securities, the Company will then make any appropriate announcements. Rather than making a premature or speculative announcement which could lead to a false market in the Company's securities, the Company's approach is to make announcements based on fact once results have been achieved.

Please do not hesitate to contact the Company should you require any further information.

For and on behalf of the Board



Gerardo Incollingo
Company Secretary
Tel: +61 2 9891 6044